Visochek Leonid, Atias Dikla, Spektor Itay, Castiel Asher, Golan Talia, Cohen-Armon Malka
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
Oncology Institute, Sheba Medical Center, Ramat Gan 53621, Israel.
Oncotarget. 2019 Oct 22;10(58):6269-6282. doi: 10.18632/oncotarget.27268.
Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80-90%) of PANC1 cancer cells in xenografts, measured 30 days after the treatment with PJ34 has been terminated. Benign cells infiltrated into the PANC1 tumors (stroma) were not affected. Growth, weight gain and behavior of the treated nude mice were not impaired during, and 30 days after the treatment with PJ34. The efficient eradication of malignant cells in human pancreas cancer xenografts presents a new model of pancreas cancer treatment.
最近的报告表明，经过修饰的菲啶PJ34能特异性根除多种人类癌细胞。它们在有丝分裂期间的根除归因于PJ34阻止了人类恶性细胞有丝分裂纺锤体极中的核有丝分裂器蛋白（NuMA）聚集，而这对其正常有丝分裂至关重要。在此，对PJ34在人胰腺导管腺癌的细胞培养物和异种移植中的作用进行了测试。结果表明，在用PJ34治疗终止30天后测量，异种移植中的PANC1癌细胞大幅减少（80 - 90%）。浸润到PANC1肿瘤（基质）中的良性细胞未受影响。在用PJ34治疗期间及治疗后30天，经治疗的裸鼠的生长、体重增加和行为均未受损。人胰腺癌异种移植中恶性细胞的有效根除为胰腺癌治疗提供了一种新模型。
